Stockreport

Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF The results were impressive, with revenues of US$14m exceeding analyst forecasts by 238%, and statutory losses of US$0.18 were likewise much smaller than the analysts ha [Read more]